Thomas Gevaert
AZ Klina · 18 works · 2,192 citations · h-index 7
Top works
- Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors
- Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research
- Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
- The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
- Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group
- Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials
- Status of Programmed Death Ligand 1 (PD-L1) by Immunohistochemistry and Scoring Algorithms
- Quantity of Immune Cells Predict Response to Immunotherapy in Cancer
- Transforming UTUC diagnostics: the potential of bladder Epicheck® in clinical practice
- A catheter-associated urinary tract infection mouse model to study bladder dysfunction and pain
- ASSESSMENT OF THE TREATMENT OF BREAST CARCINOMA WITH TOMOTHERAPY
- Primary and Solitary Intradural Extramedullary Lesion: A Diagnostic Challenge
- Assessing tumor infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology Biomarkers Working Group: Part 1: Assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research
- Prognostic role of fibroblast activation protein-α expression in non-muscle-invasive bladder cancer patients
- Progression of high-risk non-muscle invasive bladder cancer correlates with immune phenotypes and Fibroblast Activation Protein-α (FAP)
- P591 – Detailed mutational landscape and immune-oncology markers of non-muscle-invasive bladder cancer assessed using targeted gene panel sequencing
- Early recurrence in non-muscle-invasive bladder cancer is associated with aggressive transcriptomic features and stromal activation
- T1 non-muscle invasive cancers exhibit aggressive transcriptomic features despite similar survival outcomes compared to